REVIUM Rx. Research and Development Expense
REVIUM Rx. (RVRC) reported Research and Development Expense of $443.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- REVIUM Rx. research and development expense for the quarter ending 2026-06-30 was $443.00K, a 13.30% increase year-over-year.
- REVIUM Rx. research and development expense for the quarter ending 2026-03-31 was $473.00K, a 116.97% increase year-over-year.
- REVIUM Rx. research and development expense for the quarter ending 2025-06-30 was $391.00K.
- REVIUM Rx. research and development expense for the quarter ending 2025-03-31 was $218.00K.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month |
|---|---|---|
| 2026-06-30 | $443.00K 10-Q · filed 2026-08-13 | $916.00K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $473.00K 10-Q · filed 2026-05-14 | |
| 2025-06-30 | $391.00K 10-Q · filed 2026-08-13 | $609.00K 10-Q · filed 2026-08-13 |
| 2025-03-31 | $218.00K 10-Q · filed 2026-05-14 |